Skip to content
Indo Us Bio-Tech logo

Indo Us Bio-Tech

INDOUS NSE
₹65.60 −0.71 (−1.07%)
P/E
11.47
View as Markdown
MCP
Close 4 Nov 2026 ₹65.60 −68.43 −51.1% 1Y
Start ₹134.03

Key Fundamentals

MicrocapConsumer GoodsFMCG

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
14.50%
Debt to Equity
0.40
EPS (TTM)
₹5.72
Book Value
₹45.83
Market Cap
—
P/E (TTM)
11.47
P/B
1.43
ROE
15.30%
Dividend Yield
0.38%
EBITDA
₹6.90 Cr
52W High
₹159.00
52W Low
₹57.50
Day Range
₹65.00 – ₹68.92
Volume
13,617

Peer Comparison

Fast Moving Consumer Goods › FMCG › Agricultural Products › Other Agricultural Products

Indo Us Bio-Tech peer comparison
LT Foods
₹410.1022.24₹14,281 Cr2.910.73%14.70%17.60%₹11,633 Cr₹640 Cr
KRBL
₹408.6512.33₹9,318 Cr1.501.12%11.70%15.20%₹6,009 Cr₹758 Cr
Gujarat Ambuja Exports
₹152.0916.77₹6,847 Cr1.940.20%9.72%12.50%₹6,032 Cr₹416 Cr
Kaveri Seed Company
₹680.2514.02₹3,469 Cr1.730.75%15.00%15.80%₹1,279 Cr₹249 Cr
Trualt Bioenergy
₹369.4520.27₹3,167 Cr1.960.00%8.38%10.40%₹2,050 Cr₹159 Cr
Amir Chand Jagdish Kumar (Exports)
₹222.5715.79₹2,241 Cr2.330.00%15.80%15.70%₹2,627 Cr₹132 Cr
GRM Overseas
₹92.9823.84₹1,926 Cr3.210.48%14.20%14.00%₹1,869 Cr₹77 Cr
Indo Us Bio-Tech (this company)
₹65.6011.47₹137 Cr1.430.38%15.30%14.50%₹113 Cr₹11 Cr
Median 8 companies₹296.0116.28₹3,318 Cr1.950.43%14.45%14.85%₹2,338 Cr₹204 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

41 Weak

Data confidence 100/100

surveillance:ASM1

Category scores

Quality
47
Average
Returns, margins, earnings quality 22% weight
Valuation
45
Weak
Cheap vs sector & own history 24% weight
Growth
41
Weak
Sales & profit trajectory 9% weight
Financial Health
62
Good
Solvency, leverage, coverage 9% weight
Momentum
8
Poor
Trend strength, vol-adjusted 12% weight
Ownership
55
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has delivered good profit growth of 20.8% CAGR over last 5 years
  • Debtor days have improved from 64.6 to 45.5 days.
  • Company's median sales growth is 20.7% of last 10 years

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Tax rate seems low

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1270
OscillatorsBearish270
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
42.05
Neutral
MACD (12,26,9)
−1.89
Bearish
SMA (50)
75.68
Bearish
SMA (200)
96.89
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+19.20%
5Y+23.05%
3Y+21.72%
1Y+5.77%
TTM+2.53%

Net profit

Net profit growth by window
10YZero base
5Y+21.06%
3Y+22.92%
1Y−18.75%
TTM−35.58%

Operating cash flow

Operating cash flow growth by window
10Y—
5YTurned negative
3YTurned negative
1YTurned negative
TTM—

10Y: The statements do not go back far enough for this window.

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+15.45 pp
5Y+0.07 pp
3Y+0.70 pp
1Y−2.82 pp
TTM−5.08 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹24.00 Cr
Mar 2018₹29.00 Cr
Mar 2019₹35.00 Cr
Mar 2020₹40.00 Cr
Mar 2021₹39.00 Cr
Mar 2022₹49.00 Cr
Mar 2023₹61.00 Cr
Mar 2024₹73.00 Cr
Mar 2025₹104 Cr
Mar 2026₹110 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018₹1.00 Cr
Mar 2019₹2.00 Cr
Mar 2020₹3.00 Cr
Mar 2021₹5.00 Cr
Mar 2022₹5.00 Cr
Mar 2023₹7.00 Cr
Mar 2024₹8.00 Cr
Mar 2025₹16.00 Cr
Mar 2026₹13.00 Cr

Quarterly Results

₹ Cr
INDOUS quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
19.14
15.81
22.11
15.77
24.72
22.17
23.56
33.38
30.77
30.85
22.8
26.02
32.99
15.05
Expenses
16.15
13.21
17.88
14.79
21.03
17.05
18.02
28.8
25.3
26.69
18.65
22.79
29.02
17.65
Operating Profit
2.99
2.6
4.23
0.98
3.69
5.12
5.54
4.58
5.47
4.16
4.15
3.23
3.97
−2.6
OPM %
15.62%
16.45%
19.13%
6.21%
14.93%
23.09%
23.51%
13.72%
17.78%
13.48%
18.2%
12.41%
12.03%
−17.28%
Other Income
0.03
0
0.08
0.21
0.03
0.02
0.02
0.12
0
0.03
0.01
0.02
0.12
—
Interest
0.37
0.41
0.37
0.36
0.33
0.52
0.38
0.26
0.45
0.42
0.77
0.6
0.74
0.81
Depreciation
0.2
0.21
0.19
0.2
0.2
0.18
0.16
0.56
0.2
0.21
0.22
0.27
0.27
0.28
PBT
2.45
1.98
3.75
0.63
3.19
4.45
5.02
3.88
4.82
3.56
3.17
2.38
3.08
—
Tax %
3.27%
15.66%
1.87%
17.46%
0.63%
2.03%
−0.8%
4.9%
2.49%
3.09%
5.36%
17.23%
1.3%
—
Net Profit
2.37
1.67
3.68
0.52
3.17
4.36
5.05
3.68
4.7
3.45
3
1.97
3.04
−3.67
EPS (₹)
1.18
0.83
1.84
0.26
1.58
2.17
2.52
1.84
2.34
1.72
1.5
0.98
1.52
—

Sep 2026: from the results filed on 30 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
INDOUS profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
20
19
24
29
35
40
39
49
61
73
104
110
113
Expenses
19
19
23
27
32
36
34
42
51
62
85
93
97
Operating Profit
1
0
1
3
3
4
6
7
9
11
19
17
16
OPM %
3.1%
2.6%
5%
9%
10%
10%
14%
14%
15%
15%
18%
15%
14%
Other Income
0
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0
0
1
1
0
1
1
1
1
2
1
2
3
Depreciation
0
0
0
0
0
0
0
0
1
1
1
1
1
PBT
0
0
1
2
3
3
4
5
7
9
17
14
12
Tax %
−92%
−50%
25%
29%
26%
12%
−23%
5%
2%
6%
2%
6%
—
Net Profit
0
0
0
1
2
3
5
5
7
8
16
13
11
EPS (₹)
0.48
0.35
0.38
1.41
1.44
1.74
3.52
2.86
3.6
4.11
8.11
6.54
5.72
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
INDOUS balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
1
1
1
3
5
6
6
9
10
20
20
20
Reserves
1
2
2
2
9
10
15
30
44
43
58
72
Borrowings
2
5
5
7
6
9
11
12
12
14
15
37
Other Liabilities
3
6
4
6
4
10
11
4
3
7
4
4
Total Liabilities
8
14
13
17
24
35
44
56
69
84
98
133
Fixed Assets
1
1
1
2
1
1
2
6
7
7
10
11
CWIP
0
0
0
0
1
1
2
2
1
4
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
7
13
11
16
21
32
39
48
61
74
88
121
Total Assets
8
14
13
17
24
35
44
56
69
84
98
133

Cash Flow

₹ Cr
INDOUS cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
—
0
−1
−3
−1
0
3
1
2
1
−13
Investing
—
—
0
0
−3
−1
−2
−5
−7
−3
−1
−2
Financing
—
—
0
1
6
2
1
2
6
1
−1
20
Net Cash Flow
—
—
0
0
0
0
0
0
0
1
−1
6
Free Cash Flow
—
—
0
−1
−4
−1
−2
−1
−1
0
1
−15
CFO/EBITDA
—
—
11
−16
−92
−20
6
47
9
23
9
−71

Ratios

INDOUS financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
25
107
76
112
94
193
229
152
148
95
53
45
Inventory Days
91
118
92
98
176
751
—
—
—
—
—
—
Days Payable
57
115
64
71
34
667
—
—
—
—
—
—
Cash Conversion Cycle
59
110
104
138
236
276
229
152
148
95
53
45
Working Capital Days
66
33
34
59
129
137
186
257
285
266
247
248
ROCE %
14%
7%
14%
28%
20%
17%
18%
16%
15%
14%
21%
14%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Indo Us Bio-Tech insights

60 extracted metrics across FY15–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 68.29%
  • Public 24.47%
  • Others 6.98%
  • DIIs 0.25%
  • FIIs 0.01%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Indo Us Bio-Tech

What does Indo US Bio-Tech Ltd do?
Incorporated in 2004, Indo US Bio-Tech Ltd is engaged in production and processing of commercial and vegetable seeds
Where is Indo US Bio-Tech Ltd (INDOUS) listed?
Indo US Bio-Tech Ltd trades as INDOUS on the NSE and under code 541304 on the BSE.
Which sector does Indo US Bio-Tech Ltd belong to?
Indo US Bio-Tech Ltd is classified under the FMCG sector, in the Agricultural Products industry.
What is the PE ratio of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd trades at a PE ratio of 11.47 as of 4 Nov 2026, on earnings per share of ₹5.72, against a book value of ₹45.83 per share.
What is the 52-week high and low of Indo US Bio-Tech Ltd?
Over the last 52 weeks Indo US Bio-Tech Ltd has traded between ₹57.5 and ₹159 as of 4 Nov 2026.
Does Indo US Bio-Tech Ltd pay dividends?
Indo US Bio-Tech Ltd has a dividend yield of 0.38%.
What is the Return on Equity (ROE) of Indo US Bio-Tech Ltd?
Indo US Bio-Tech Ltd reported a return on equity of 15.30%. Its debt-to-equity ratio is 0.40.

Company Information

Incorporated in 2004, Indo US Bio-Tech Ltd is engaged in production and processing of commercial and vegetable seeds

Website indousagriseeds.com
CEO Mr. Jagdishkumar Devjibhai Ajudia
Listed 27 Sep 2024
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INDOUS.md for Indo US Bio-Tech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Agri & Food Products stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month